ATE244713T1 - Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) typs 4 und des tumor-necrosin-factors (tnf) - Google Patents

Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) typs 4 und des tumor-necrosin-factors (tnf)

Info

Publication number
ATE244713T1
ATE244713T1 AT97921992T AT97921992T ATE244713T1 AT E244713 T1 ATE244713 T1 AT E244713T1 AT 97921992 T AT97921992 T AT 97921992T AT 97921992 T AT97921992 T AT 97921992T AT E244713 T1 ATE244713 T1 AT E244713T1
Authority
AT
Austria
Prior art keywords
pde
phosphodiesterase
tnf
inhibitors
factor
Prior art date
Application number
AT97921992T
Other languages
English (en)
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE244713T1 publication Critical patent/ATE244713T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT97921992T 1996-06-25 1997-06-02 Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) typs 4 und des tumor-necrosin-factors (tnf) ATE244713T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25
PCT/IB1997/000630 WO1997049702A1 (en) 1996-06-25 1997-06-02 Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors

Publications (1)

Publication Number Publication Date
ATE244713T1 true ATE244713T1 (de) 2003-07-15

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97921992T ATE244713T1 (de) 1996-06-25 1997-06-02 Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) typs 4 und des tumor-necrosin-factors (tnf)

Country Status (43)

Country Link
US (1) US6040329A (de)
EP (1) EP0912558B1 (de)
JP (1) JP3152940B2 (de)
KR (1) KR20000022516A (de)
CN (1) CN1080260C (de)
AP (1) AP1025A (de)
AR (1) AR007456A1 (de)
AT (1) ATE244713T1 (de)
AU (1) AU716376B2 (de)
BG (1) BG64052B1 (de)
BR (1) BR9712782A (de)
CA (1) CA2258285C (de)
CO (1) CO4900056A1 (de)
CZ (1) CZ423398A3 (de)
DE (1) DE69723447T2 (de)
DK (1) DK0912558T3 (de)
DZ (1) DZ2254A1 (de)
EA (1) EA002274B1 (de)
ES (1) ES2201299T3 (de)
GT (1) GT199700075A (de)
HK (1) HK1018700A1 (de)
HN (1) HN1997000079A (de)
HR (1) HRP970350B1 (de)
HU (1) HUP9903009A3 (de)
ID (1) ID18579A (de)
IL (1) IL127036A (de)
IS (1) IS4910A (de)
MA (1) MA24225A1 (de)
MY (1) MY116915A (de)
NO (1) NO986103L (de)
NZ (1) NZ332752A (de)
OA (1) OA10934A (de)
PA (1) PA8432301A1 (de)
PL (1) PL330974A1 (de)
PT (1) PT912558E (de)
SI (1) SI0912558T1 (de)
SK (1) SK176598A3 (de)
TN (1) TNSN97108A1 (de)
TR (1) TR199802685T2 (de)
TW (1) TW434237B (de)
WO (1) WO1997049702A1 (de)
YU (1) YU60198A (de)
ZA (1) ZA975581B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
CN1234031A (zh) * 1996-09-04 1999-11-03 辉瑞大药厂 吲唑衍生物及其作为磷酸二酯酶(pde)iv型和肿瘤坏死因子(tnf)产生的抑制剂的应用
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
ID24942A (id) * 1997-11-04 2000-08-31 Pfizer Prod Inc Senyawa terapi aktif yang berdasarkan penggantian bioisoster katekol dengan indazole pada inhibitor pde4
AU770918B2 (en) * 1999-12-23 2004-03-11 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
CA2440842A1 (en) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compounds
BRPI0117198B1 (pt) 2001-12-14 2018-03-13 Merck Serono S.A. Usos de composição compreendendo um inibidor seletivo de uma isoforma 4 de fosfodiesterase
NZ537725A (en) 2002-07-19 2006-08-31 Memory Pharm Corp 6-Amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
US7405230B2 (en) 2002-07-19 2008-07-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
NZ540138A (en) * 2002-11-19 2008-07-31 Memory Pharm Corp Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
KR20060005375A (ko) * 2003-04-18 2006-01-17 메모리 파마슈티칼스 코포레이션 포스포디에스테라제 4 억제제로서의 피라졸 유도체
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
CN101166733A (zh) 2004-10-15 2008-04-23 记忆药物公司 作为磷酸二酯酶4抑制剂的吡唑衍生物
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
WO2006129158A2 (en) * 2005-05-30 2006-12-07 Ranbaxy Laboratories Limited 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007029077A1 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN103497185A (zh) 2007-03-14 2014-01-08 兰贝克赛实验室有限公司 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2651296T3 (es) * 2009-10-30 2018-01-25 Janssen Pharmaceutica, N.V. Derivados de imidazo[1,2-b]piridacina y su uso como inhibidores de PDE10
EP2804603A1 (de) 2012-01-10 2014-11-26 President and Fellows of Harvard College Betazellen-replikation für promoterverbindungen und verwendungsverfahren dafür
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
EP3137454A1 (de) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatische verbindungen und deren verwendung als dopamin-d1-liganden
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (de) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
NZ251092A (en) * 1992-04-02 1996-12-20 Smithkline Beecham Corp 4-cyano-cyclohexane derivatives; medicaments; used in treating asthma
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
AU702105B2 (en) * 1994-10-20 1999-02-11 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体

Also Published As

Publication number Publication date
EP0912558A1 (de) 1999-05-06
JPH11514668A (ja) 1999-12-14
DK0912558T3 (da) 2003-08-18
SI0912558T1 (en) 2003-10-31
PA8432301A1 (es) 1999-12-27
CO4900056A1 (es) 2000-03-27
JP3152940B2 (ja) 2001-04-03
CZ423398A3 (cs) 1999-12-15
EA002274B1 (ru) 2002-02-28
TR199802685T2 (xx) 1999-03-22
NO986103D0 (no) 1998-12-23
HK1018700A1 (en) 1999-12-30
ID18579A (id) 1998-04-23
BR9712782A (pt) 1999-12-07
HRP970350A2 (en) 1998-06-30
AP1025A (en) 2001-11-19
HRP970350B1 (en) 2003-04-30
HN1997000079A (es) 1997-12-26
OA10934A (en) 2002-02-18
KR20000022516A (ko) 2000-04-25
EA199801047A1 (ru) 1999-06-24
TNSN97108A1 (fr) 2005-03-15
IL127036A0 (en) 1999-09-22
SK176598A3 (en) 2000-06-12
BG103056A (en) 1999-10-29
DE69723447D1 (de) 2003-08-14
TW434237B (en) 2001-05-16
HUP9903009A3 (en) 2002-01-28
BG64052B1 (bg) 2003-11-28
MY116915A (en) 2004-04-30
HUP9903009A2 (hu) 2000-05-28
AU716376B2 (en) 2000-02-24
YU60198A (sh) 1999-09-27
PT912558E (pt) 2003-11-28
ES2201299T3 (es) 2004-03-16
MA24225A1 (fr) 1997-12-31
WO1997049702A1 (en) 1997-12-31
NZ332752A (en) 2001-04-27
AP9701020A0 (en) 1997-07-31
ZA975581B (en) 1998-12-24
CN1080260C (zh) 2002-03-06
DE69723447T2 (de) 2003-12-24
CA2258285A1 (en) 1997-12-31
IS4910A (is) 1998-11-27
CN1223651A (zh) 1999-07-21
DZ2254A1 (fr) 2002-12-18
IL127036A (en) 2001-06-14
EP0912558B1 (de) 2003-07-09
AR007456A1 (es) 1999-10-27
CA2258285C (en) 2002-11-26
PL330974A1 (en) 1999-06-21
NO986103L (no) 1998-12-23
AU2785797A (en) 1998-01-14
US6040329A (en) 2000-03-21
GT199700075A (es) 1998-12-04

Similar Documents

Publication Publication Date Title
ATE244713T1 (de) Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) typs 4 und des tumor-necrosin-factors (tnf)
ATE292626T1 (de) Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) des typs iv und der produktion des tumor nekrosis faktors (tnf)
DE59913617D1 (de) Indolderivate und deren Verwendung als Inhibitoren der Phosphodiesterase 4.
AU3781397A (en) Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
ATE202347T1 (de) Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren
ATE268761T1 (de) Substituierte quinazolin-derivate und ihre verwendung als tyrosin-kinase inhibitoren
DE69826662D1 (de) 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
HU9702036D0 (en) New heterocyclic compounds as inhibitors of leucocita-adhesion and wla-4-antagonists
DE69722656D1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
NO980718D0 (no) Bicykliske 4-aralkylaminopyrimidinderivater og tyrosinkinaseinhibitorer
SG43951A1 (en) Use of indole derivatives as 5HT1 antagonists
AU3261293A (en) Heterocyclic sulfonamide derivatives as antagonists of paf and angiotensin II
DE69708629D1 (de) Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren
HK1066804A1 (en) Derivatives of indole and their use as phosphodiesterase 4 inhibitors
DE69821988D1 (de) Substituierte isochinoline derivate und ihre verwendung als anticonvulsiva

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0912558

Country of ref document: EP

REN Ceased due to non-payment of the annual fee